Retrospective review of brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in children and adolescents (< 18 years) with early relapse Hodgkin lymphoma
Latest Information Update: 23 Apr 2021
Price :
$35 *
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2021 Results published in the Journal of Pediatric Hematology/Oncology
- 04 Jun 2019 Results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 04 Jun 2019 New trial record